SciClone Pharmaceuticals (Holdings) Ltd 06600
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 18.12
- Day Range
- HKD 18.04–18.14
- 52-Week Range
- HKD 8.75–18.28
- Bid/Ask
- HKD 18.06 / HKD 18.08
- Market Cap
- HKD 11.32 Bil
- Volume/Avg
- 3.8 Mil / 5.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 8.07
- Price/Sales
- 3.38
- Dividend Yield (Trailing)
- 2.15%
- Dividend Yield (Forward)
- 2.15%
- Total Yield
- 9.11%
Company Profile
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,046
- Website
- https://www.sciclone.com
Comparables
Valuation
|
Metric
|
06600
|
RGC
|
02552
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.07 | — | — |
Price/Book Value | 3.16 | 5.77 | — |
Price/Sales | 3.38 | — | 18.32 |
Price/Cash Flow | 7.13 | — | — |
Price/Earnings
06600
RGC
02552
Financial Strength
|
Metric
|
06600
|
RGC
|
02552
|
|---|---|---|---|
Quick Ratio | 4.46 | 19.15 | 3.53 |
Current Ratio | 4.94 | 19.15 | 3.80 |
Interest Coverage | 20.71 | — | −36.00 |
Quick Ratio
06600
RGC
02552
Profitability
|
Metric
|
06600
|
RGC
|
02552
|
|---|---|---|---|
Return on Assets (Normalized) | 31.49% | −33.37% | −14.39% |
Return on Equity (Normalized) | 43.39% | −35.23% | — |
Return on Invested Capital (Normalized) | 36.01% | −34.27% | −55.97% |
Return on Assets
06600
RGC
02552
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Jvpttmwqq | Myk | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Rpkvjqxk | Zgmxst | $70.9 Bil | |
HLN
| Haleon PLC ADR | Qpdttrngq | Hmjb | $37.8 Bil | |
VTRS
| Viatris Inc | Bdgfmqfbw | Tsqz | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mwmwcdlj | Mmdk | $12.7 Bil | |
CTLT
| Catalent Inc | Tlqbczlz | Gkvyxf | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Ljcpfgzs | Dsjln | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Txckjvy | Rrm | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Lplfbfdqs | Bvzqsw | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Zwzlzxvky | Tkngj | $3.1 Bil |